At Ace Therapeutics, our scientists are committed to developing and validating custom carbomer-induced glaucoma models. With years of experience in ophthalmic disease modeling, we provide robust, reproducible models that replicate human glaucoma pathophysiology, enabling precise investigation of intraocular pressure (IOP) dynamics, axonal transport deficits, and neuroprotective strategies.
Overview of Carbomer-Induced Glaucoma Models
Carbomer, a polyvinyl carboxy polymer, is widely used in ophthalmic research to induce glaucoma models. Carbomer-induced glaucoma is a well-established preclinical model that generates moderate, sustained IOP elevation, closely mimicking the chronic ocular hypertension observed in human primary open-angle glaucoma. By injecting carbomer into the anterior chamber, this model induces trabecular meshwork (TM) obstruction, leading to aqueous humor (AH) outflow resistance and IOP elevation. This ultimately results in retinal ganglion cell (RGC) loss and optic nerve degeneration.
Fig. 1 Retinal ganglion cell survival in carbomer-injected eye after a single injection of carbomer solution. (Kim H G, et al., 2013)
Our Carbomer-Induced Glaucoma Model Customization Services
We specialize in developing custom carbomer-induced animal models, which are crucial for in-depth preclinical glaucoma research. We offer customized protocols, adjusting carbomer concentration, injection volume, and monitoring timelines to match your study goals.
Ace Therapeutics has developed carbomer-induced glaucoma models in rodents and rabbits. By injecting a 0.3% carbomer solution into the anterior chamber of rat eyes, our scientists can effectively induce chronic IOP elevation that lasts for up to 8 weeks.
Key Characteristics of Our Carbomer-Induced Glaucoma Models
- Controlled IOP elevation
Gradual, sustained increase, free from acute spikes and with relatively small IOP fluctuations. - Pathological relevance
Retinal nerve fiber layer (RNFL) thinning, RGC apoptosis, and optic nerve damage.
Advantages of Our Carbomer-Induced Glaucoma Models
- High reproducibility
- Adjustable IOP profiles
- Chronic progression
Ace Therapeutics supports targeted investigation of RGC vulnerability and pressure-mediated neurodegeneration through customizable induction protocols and longitudinal monitoring tailored to specific research needs.
Assessment Technologies for Carbomer-Induced Glaucoma Models
With our ocular phenotyping tools, Ace Therapeutics provides a range of testing services, including but not limited to:
- IOP monitoring
Non-invasive tonometry and invasive manometry. - Functional assessment
Electroretinography (ERG), optokinetic response (OKR), and visual acuity testing. - Structural imaging
Optical coherence tomography (OCT). - Histopathology
Routine histology and immunohistochemistry (IHC).
With a wealth of experience in preclinical glaucoma studies, Ace Therapeutics is an ideal partner for your preclinical studies. Whether you are focused on IOP modulation, neuroprotection, or novel drug delivery systems, our expertise ensures your research is grounded in translational relevance and scientific rigor. Contact us now and explore our carbomer-induced models!
Reference
- Kim H G, et al. Experimental chronic ocular hypertension by anterior chamber injection of 0.3% carbomer solution in the rat. Clin Exp Ophthalmol, 2013, 41(4): 404-412.